Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to investigate possible factors that will affect the choice of androgen deprivation therapy in prostate cancer patients. This is a cross-sectional study performed in Prince of Wales Hospital in Hong Kong. One hundred patients will be recruited for this study.
The incidence of prostate cancer in Hong Kong almost tripled between 1996 and 2010, with the highest increased incidence rate in total forms of malignancy. The incidence of prostate cancer in Hong Kong increased up to 28.9 per 100,000 men in 2017 (Age-standardized rate) (Hong Kong Cancer Registry 2017) and ranked third in all men cancers in Hong Kong. Certain environmental elements have had an effect on the increased rate of prostate cancer, including the transition to Western dietary habits and an aging population because of the rise in average life expectancy. In addition to environmental causes, the medical development of laboratory diagnoses and wide prostate-specific antigen usage in Hong Kong have also contributed to the increase in diagnosis of prostate cancer in recent years. Certainly, the efforts from different health bodies in public education about the condition have helped to raise public awareness about the condition, which also increase the pick-up of early disease in Hong Kong.
Androgen deprivation treatment (ADT) has become the standard treatment for metastatic prostate cancer in the past decades. Androgen deprivation can be achieved by three main modalities, namely bilateral orchidectomy, gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist. Apart from injectable ADT, oral GnRH antagonist has been approved recently. ADT can be different in terms of mechanism of action, route of drug administration (injection vs oral), site of injection and frequency of drug administration. Each different formulation may contribute to patient's choice on their drug usage [1-3]. However, information regarding the preference of choice and factors affecting the choice of ADT formulation were not available in the literature. Therefore, in this study, possible factors that will affect patient's choice of ADT, reason and preference on their ADT choice will be investigated.
The objective of this study is to investigate possible factors that will affect patient's choice of ADT therapy. This is a cross-sectional study performed in Prince of Wales Hospital in Hong Kong. One hundred patients will be recruited for this study.
After obtaining informed consent, trained research staffs will assist the subjects to perform this cross-sectional survey. Information related to patients' background (including, but not limited to: age, educational level, work-status, living situation), disease background (stage of disease), concomitant drug usage & administrative frequency, preference on drug usage (ADT vs injection; frequency of drug administration), history of ADT usage, reason and preference on their ADT choice, will be collected from the survey.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Prostate Cancer | Patients diagnosed with prostate cancer |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | No intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Possible factors that will affect patient's choice of ADT therapy | Possible factors that will affect patient's choice of ADT therapy | 1 year |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Prostate cancer only happens in male patients
Not provided
Patients diagnosed with prostate cancer in Prince of Wales Hospital will be identified in specialist clinics and then enrolled to the study,
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Chi Fai NG, MD | Chinese University of Hong Kong | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prince of Wales Hospital | Shatin | Hong Kong |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30120753 | Background | Psarou A, Cooper H, Wilding JPH. Patients' Perspectives of Oral and Injectable Type 2 Diabetes Medicines, Their Body Weight and Medicine-Taking Behavior in the UK: A Systematic Review and Meta-Ethnography. Diabetes Ther. 2018 Oct;9(5):1791-1810. doi: 10.1007/s13300-018-0490-5. Epub 2018 Aug 17. | |
| 32753849 | Background |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S. Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire. Patient Prefer Adherence. 2020 Jul 2;14:1093-1102. doi: 10.2147/PPA.S251812. eCollection 2020. |
| 14640142 | Background | Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19. |
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |